Monthly Archives: June 2020

More than 8 million Italians tune in as football returns – Macau Business

Posted: June 13, 2020 at 3:15 pm

The return of Italian football was a hit with television viewers in the country as more than eight million tuned in to watch the cup semi-final second leg between Juventus and AC Milan on Friday.

The match was the first to be played in Italy since the coronavirus pandemic halted the season on March 9.

The 0-0 stalemate, which was enough to send Juventus to the final, drew the biggest TV audience for a football match this term, Italian media reported on Saturday.

When he authorised the resumption of football, Italian Sports Minister Vincenzo Spadafora welcomed the fact the first matches would be in the Italian Cup, as they are broadcast free-to-air on national network RAI and are thus accessible to everyone.

On Friday, the match attracted almost 8.3 million viewers on RAI 1, with a 34 per cent market share.

The biggest audience before the lockdown was for the first legof the semi-final which ended 1-1 attracted 8.09 million viewers.

The national team, whose matches are also broadcast free-to-air on RAI, attracted 7.4 million viewers for their Euro 2020 qualifier against Bosnia last June.

Read this article:

More than 8 million Italians tune in as football returns - Macau Business

Posted in Macau | Comments Off on More than 8 million Italians tune in as football returns – Macau Business

New Psychedelics Stocks and Acquisitions | 2020-06-08 | Investing News – Stockhouse

Posted: at 3:12 pm

2020 is the year of many things: global conflict, devastating fires, the COVID-19 pandemic, and now civil unrest in response to racism and police brutality in the United States.

It’s been a tough year for everyone, but it has also brought about renewed conversations on societal progress. How can we improve, where do we go from here, and what changes can we start to make?

Strangely to some, one of those changes is coming in the normalization of psychedelics to treat medical conditions. What was once a stigmatized and prohibited class of substances is quickly having a second wind as a treatment for depression, PTSD, and substance-abuse disorders amongst a handful of many other potential therapeutic needs.

We’re also now starting to deal with a wave of new (and previously undiagnosed) cases of depression and anxiety on the back of the COVID-19 pandemic. One week into June, we’re quickly approaching a point where many people have been at home with limited social interaction (or physical activity) for months on end.

As if on queue, the market for psychedelics companies has started to open up in a big way. More and more companies directly and indirectly invested in psychedelics are coming to public markets, and others are starting to make their moves into psychedelics widely known. 2020 is the year of many things, and it’s looking like psychedelics is one of them.

Back in May, we highlighted the impressive rise of a few of the companies involved in the psychedelics market. Those included the recently-public psychedelics companies Champignon Brands Inc. (CSE:SHRM) and Mind Medicine Inc. (NEO:MMED), as well as indirect investments like those of Yield Growth Corp. (CSE:BOSS) and Revive Therapeutics Ltd. (CSE:RVV).

Fast-forward a few weeks and we’ve seen even more companies enter the fray. On May 20, fully-integrated psychedelics company Numinus Wellness Inc. (TSX-V:NUMI) went public, with business arms in clinic and therapy operation, research and development, and direct selling and distribution of psychedelics. On May 28, Ontario-based Red Light Holland Corp. (CSE:TRIP) also began listing with a plan to produce and sale psilocybin in the legal Netherlands market for the time being.

We’re also seeing an increasing wave of acquisitions and pivots into psychedelics from companies previously invested in healthcare, cannabis, and even technology. German medical cannabis distributor Pharmadrug Inc. (CSE:BUZZ) acquired Dutch psychedelics retailer Super Smart, California cannabis company Hollister Biosciences Inc. (CSE:HOLL) closed their acquisition of mushroom-based health product developer AlphaMind Brands Inc., and eCommerce CBD provider Mota Ventures Corp. (CSE:MOTA) acquired pharmaceutical psilocybin manufacturer Verrian Ontario Ltd.

And that’s not including the previous moves of companies like New Wave Holdings Corp. (CSE:SPOR) in psychedelics and esports, Empower Clinics Inc. (CSE:CBDT) in creating its own psilocybin and psychedelics division, and NewLeaf Brands Inc. recently adding a focus on psychedelics and rebranding as Mydecine Innovations Group Inc. (CSE:MYCO).

No matter where you look, people and companies are getting invested in psychedelics. Though this has been a somewhat comprehensive list, there are too many to include and more are continuing to pile in. With more excitement about psychedelics and their importance on one hand, and more viable investing options entering the markets on the other, the future for these alternative medicines seems bright.

New to investing in Healthcare? Check out Stockhouse tips on How to Invest in Healthcare Stocks and some of our Top Healthcare Stocks.

For more of the latest info on Cannabis, check out the Healthcare Trending News hub on Stockhouse.

FULL DISCLOSURE: Yield Growth Corp. is a client of Stockhouse Publishing

View original post here:

New Psychedelics Stocks and Acquisitions | 2020-06-08 | Investing News - Stockhouse

Posted in Psychedelics | Comments Off on New Psychedelics Stocks and Acquisitions | 2020-06-08 | Investing News – Stockhouse

Pure Extracts: The Second Wave of Psychedelic Operators – The Deep Dive

Posted: at 3:12 pm

Some years ago when the first wave of cannabis firms went public, operators were focused on building a narrative behind one common theme: capacity. Specifically, investment bankers and business executives were focused on touting the square footage of their facility, which in layman terms, could be converted into revenue. If an operator has X square feet, it translates into Y plants, and conversely, Z revenue.

Despite touting their own company as the best potential operator in the space, collectively, these investment bankers and executives would collaborate on one topic: the size of the market as a whole, which every year was grown by a few hundred million to entice further investment dollars.

The trouble however, was that these operators were focused on top line revenue potential, and not whether they could actually turn a profit.

Fast forward to the end of the boom and bust cycle, and numerous of these operators are now being sold off for pennies on the dollar, and seemingly have learnt nothing. Few cultivators show promise of generating profits at any point in the future, despite having years to develop proper processes and achieve profitability.

The second wave of operators, referred to commonly as extractors, are in a different category altogether however. Having seen the vast failures exhibited by the first round of contestants, these operators typically focused on a different financial metric: profitability. Having realized the need for certain services within the sector, namely the extraction of cannabinoids for the purpose of oils and cannabis 2.0 products, these operators set out to provide a service that was in high demand within the space and while being able to turn a profit at the same time.

Looking to the burgeoning psychedelics space, and things altogether have not changed much. While the first wave of operators have focused largely on a biotech angle, full of high clinical study costs and potential target markets for proposed cures to ailments, the already oncoming second wave is looking to tackle the space from a different angle.

Presently, that second wave only consists of Pure Extracts (Private), a gray market operator that has entered the legal side of operations. Well known for its years of producing premium quality, full spectrum oil (FSO) Pure Pulls vape pens within the gray market, the operator is now in the process of finalizing its licensing to process cannabis and hemp biomass. Given the strong experience behind it, the Company has already signed two tolling agreements for a total of 120,000 kgs/annum of hemp and cannabis despite not quite having its license yet, although it is believed to be imminent. Despite being significantly impressive, this isnt even the most interesting part of Pure Extracts story.

That is reserved for the Companys step into the psychedelics space. Rather than focus on biotech themselves, the Company has come to the realization that all these studies will require one key ingredient psilocybin extract. As a result, Pure Extracts is submitting its Dealers License application to Health Canada to enable the Company to extract this ingredient for operators in the space that need it to conduct clinical studies. Psilocybin extract, given its relative scarcity, is currently a high value item, and currently fetches upwards of $10,000 per gram.

Outside of research purposes, there is also currently a large demand for functional mushroom extracts think already legal markets for non-psychoactive variants. Here, the functional mushroom market is one of the fastest growing CPG segments. With research showing mushrooms containing properties such as immune boosting, detoxification, anti-tumor, and anti-viral and more the race is currently on for extractors to step into the growing segment. Many extraction competitors are unready for the new psychedelic and functional mushroom markets, whereas Pure Extracts is already moving with precision to tackle the segment head-on. The segment offers massive opportunity for those who elect to grab a first mover advantage.

In this regard, Pure Extracts has laid out a simple business development strategy. Theyve positioned themselves in a manner that enables them to become the premier commercialization and manufacturing partner for both functional and psychedelic firms within the space. While initial products under this operating segment will be focused on functional products, the Company is submitting an application for its Dealers License as previously mentioned, which will enable them to buy, sell, test and product psychedelics within an EU GMP environment.

Here, Canadas ability to export such products around the world, combined with Pure Extracts Good Production Practice (GPP) facility will enable the Company to be a prime partner for both functional and psychedelic mushroom firms. Furthermore, the Company has already set the strategy in motion, having signed several NDAs with functional product firms to explore joint development strategies. These product lines are currently targeting a third quarter 2020 launch.

While new operators seemingly appear each week within the biotech-based psychedelic space, Pure Extracts offers a compelling type of exposure to the niche market that has yet to be addressed. The need for such extracts is apparent given the growth in the sector, however the lack of competition gives Pure Extracts an early edge in what is set to be a high demand segment.

Pure Extracts is set to IPO in the coming months.

FULL DISCLOSURE: Pure Extracts is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pure Extracts on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dives stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.

Go here to see the original:

Pure Extracts: The Second Wave of Psychedelic Operators - The Deep Dive

Posted in Psychedelics | Comments Off on Pure Extracts: The Second Wave of Psychedelic Operators – The Deep Dive

New analysis claims the FDA rushed ketamine’s approval for depression treatment – Big Think

Posted: at 3:12 pm

There was a lot of excitement when the FDA fast-tracked ketamine trials for depression treatment in 2016. The announcement marked a major turning point in our understanding of psychedelics, which were deemed a Schedule 1 substance as part of Richard Nixon's racist 1970 "War on Drugs." Ketamine was approved for use as an anesthetic that same year; due to increasing recreational usage in the 1990s, however, it was deemed Schedule III in America in 1999.

Though ketamine is not a traditional psychedelicthey have an agonist (or partial agonist) effect at brain serotonin 5-HT2A receptorsit falls into this class due to its hallucinogenic and dissociative effects. Recently it has been referred to as a "party psychedelic." Psychedelic therapy advocates were pleased when the FDA approved a nasal spray medication for treatment-resistant depression known as esketamine in 2019. Janssen Pharmaceuticals launched Spravato shortly after.

This move is exciting. Trials of two types of ketamineracemic ketamine and esketamineshowed early positive results, even though researchers are not exactly sure how it functions in depression treatment. We do know antidepressants and antipsychotics are showing less efficacy and more chronic side effects than previously believed, however.

There is precedent in the psychedelic realm. Psilocybin, ayahuasca, ibogaine, MDMA, and LSD are showing early positive results in treating anxiety, depression, addiction, and PTSD. This does not mean we should rush blindly ahead, however.

That's the consensus reached by Mark Horowitz (writer) and Joanna Moncrieff (editor), whose recent analysis, published in The British Journal of Psychiatry, concludes that we're moving too fast in clinically adopting ketamine. As their data shows, caution is necessary.

Since its discovery in 1962, ketamine has been used broadly as a sedative and anesthetic; to aid in emergency surgeries in war zones; as a bronchodilator for severe asthmatics; to treat certain type of seizures; in postoperative pain management; and now, as a nasal spray to treat depression. Unlike SSRIs and SNRIs, esketamine works immediatelyin as little as two hoursmaking it more attractive to patients and clinicians.

While treatment-resistant depression sounds extreme, Horowitz notes the definition: patients unsuccessful with two different antidepressants, a low bar for the term "resistant." The problem with trying esketamine, he writes, falls back on the FDA fast-tracking of the drug.

"Out of the three short-term trials conducted by Janssen only one showed a statistically significant difference between esketamine and placebo. These were even shorter than the 68 week trials the FDA usually requires for drug licensing."

Each trial lasted only four weeks. The FDA normally requires that two such trials show better results than the placebo; in this case, only one achieved this goal. The successful trial showed a four-point margin on a scale that goes to 60.

Failing to provide two effective trials, the FDA allowed Janssen to submit a discontinuation trial as evidence. This 16-week trial let patients either continue or stop treatment. The problem: side effects were treated as evidence of relapse, not withdrawal symptoms.

Ketamine users have a long history of withdrawal issues, including anxiety, poor appetite, delusions, hallucinations, paranoia, addiction, rage, and craving. The discontinuation trial considers such effects as proof of ketamine's efficacy, not as symptoms of withdrawal.

Science writer Peter Simons explains why this is worrisome:

"Perhaps even more concerning is the fact that, within the discontinuation trial, a single site in Poland drove the apparent finding of efficacy. Data from this site suggested that 100% of the placebo group supposedly relapsed (compared with about 33% of the placebo group in all the other sites)an unlikely result. When data from this suspicious outlier was removed, the study analysis showed no evidence that esketamine was better than the placebo."

Add to this that six people in the esketamine group died during the trials, including three by suicidetwo of whom had previously shown no signs of suicidal ideationsand a troubling picture emerges. The FDA accepted Janssen's explanation: the problem wasn't esketamine, but their underlying condition. This is possible, but the company did not provide conclusive evidence.

Jennifer Taubert, executive vice president and worldwide chairman of Janssen Pharmaceuticals, Johnson & Johnson, testifies before the Senate Finance Committee on "Drug Pricing in America: A Prescription for Change, Part II" February 26, 2019 in Washington, DC. The committee heard testimony from a panel of pharmaceutical company CEOs on the reasons for rising costs of prescription drugs.

Photo by Win McNamee/Getty Images

According to Horowitz, this is a chronic problem with clinical trials and governing agencies.

"It would seem that themes from history are repeating: a known drug of misuse, associated with significant harm, is increasingly promoted despite scant evidence of efficacy and without adequate longterm safety studies."

He also notes that half of the patients experienced disassociation and one-third experienced dizziness. On this point, allow me to break the fourth wall. I've been experimenting with psychedelics since 1994 and am writing a book on psychedelics in ritual and therapy. I ingested a range of substances during my college years. By far, the most troublesome was ketamine. While I'm now aware of Parecelsus's dictumwhat is beneficial in small doses is toxic in large dosesI wasn't measuring it out in the 1990s.

Administered doses in Janssen's trials were considered similar to recreational usage. I recall that a bump provided an energetic lift, yet when I'd occasionally snort a line, all bets were off. After a hearty dose one evening, I laid down, sat up, and stood in succession. I couldn't tell the difference between those three physical positions. Ketamine is the most dissociative substance I've ever taken, and I stopped shortly after that last instance.

Psychedelics are the next wave of mental health treatmentscall it a continuation, given their role in traditional rituals. We came to rely on pharmacology too much in the twentieth century; hopefully we're learning from those mistakes. As Horowitz points out, however, it appears we're not.

The important word in psychedelic therapy is ritual. There are environmental and social factors entwined with our health. In the right context, psychedelics have tremendous healing power. And to be fair, some ketamine clinics are taking proper right safety precautions as well as designing treatment rooms to be more conducive to healing than sterile white rooms. Patients are anecdotally reporting success in depression treatment with ketamine. This isn't an either-or situation.

But we cannot make the same mistake we've made with CBD and believe these substances are cure-alls. We also can't afford to designate ketamine under the umbrella term "psychedelics." As Alan Watts wrote, hallucinogen is not a proper definition of the psychedelic experience, though it's fitting when describing ketamine. Conflating substances will only further confusion during a time when we need clarity. If the addictive properties and dangerous side effects of ketamine play out widely, it endangers the entire psychedelic therapy model.

We can hope for a clinically-effective dosage and delivery mechanism of ketamine. We can't, as Horowitz's analysis shows, make the same mistakes over. Pharmacological intervention has a place in psychiatry, but it's come to dominate the industry, often no better than placebo and psychotherapy. We need healing, not more side effects.

--

Stay in touch with Derek on Twitter, Facebook and Substack. His next book is "Hero's Dose: The Case For Psychedelics in Ritual and Therapy."

From Your Site Articles

Related Articles Around the Web

Read the original post:

New analysis claims the FDA rushed ketamine's approval for depression treatment - Big Think

Posted in Psychedelics | Comments Off on New analysis claims the FDA rushed ketamine’s approval for depression treatment – Big Think

How Liv Vasquez Uses Plants & Food for Wellness and Healing – Thrillist

Posted: at 3:12 pm

As people face their issues, Vasquez is there to call out trauma responses so they know to soothe those reactions and keep working through it. While the cannabis, journaling, and talk therapy work helps soothe and process triggers, the psychedelic element can allow you to go deeper into the cause of that trigger.

"In small amounts, on a controlled schedule, you can process a lot of trauma very quickly with psychedelics," says Vasquez. Even those small amounts can shine a light on dark corners of your memory. You dont always know what you will find in those corners. I just let my clients know that they are safe and that I am here for them on the other side of it. When they come back for our next session, we unpack it together.

One thing Vasquez is clear about is that there is no one perfect dose. And there is often trial and error when first laying down dosing guidelines and a schedule. But thats why the communication and journaling are as important an element as the treatments themselves.

Oftentimes, her clients are on the right track when she meets them. They are on their way to getting to the root of their issues, and what she does can help expedite that process by lifting some of the barriers halting their progress. She explains how unresolved trauma can be a distracting burden in this internal work. How living with trauma is like trying unsuccessfully to sleep soundly every night and going through days half exhausted and half awake.

When you acknowledge what triggers your reactions and the feelings that are rooted in trauma, it can free up space in your life, says Vasquez.

"One of my clients is a medium and a mom, she continues. Mediums already kind of live on two planes, and you have to make a LOT of boundaries with ghosts. It can take a lot of energy. She came to me because she was having problems being fully present in both her day-to-day life and her spirit work.

After six weeks of work with Vasquez, on a regimen that included microdosing mushrooms and CBD with low doses of THC on a controlled schedule, the client reported an enormous difference in her day-to-day clarity. In that case, her client just needed help utilizing her time on both planes more efficiently. And Vasquez helped her do so.

Right now, were all doing more internal work during quarantine. If youre experimenting with different modes of wellness, Vasquez recommending everyone start by journaling every step of the way.

When you're starting any new journey in plant-based medicine, or even a new diet, you must be gentle with yourself, explains Vasquez. Start by microdosing once a month, and listen to your mind and your body as you go. Cannabis and psychedelics can affect your psyche so it is important to note your observations and effects in order to make those judgment calls about dose and schedule.

Vasquez also highly recommends having someone to talk to. As a sort of safety net that helps you process the experience, the talk therapy is as important as the substances themselves. Her favorite part of her work is being that perspective; that ally at her clients side as they work through those triggers.

"Helping others with trauma helps me understand my own trauma, she says. When you live with PTSD, and help people with PTSD, there is just no feeling like it. Its validating. I feel like I have truly stepped into my power.

Originally posted here:

How Liv Vasquez Uses Plants & Food for Wellness and Healing - Thrillist

Posted in Psychedelics | Comments Off on How Liv Vasquez Uses Plants & Food for Wellness and Healing – Thrillist

Reiki that – how some Americans use alternative medicine to deal with stress – Yahoo News

Posted: at 3:11 pm

When Black Lives Matter protests started around the world, Reiki Level 3 student, Indra Gandy, decided to use her skills in the alternative healing technique to help.

"At this point, I become a conduit of positive energy," Gandy described the Reiki ritual she performed on a pier bench, a walking distance from her Staten Island home. "You are purposely giving them love and pure energy, health, stability and positive strength."

Reiki, which was developed in Japan in early 20th century, is often described as alternative medicine through energy healing.

In Japanese, the first part of the word, 'rei,' means "spiritual" and the second, 'ki,' stands for 'vital energy' or 'life force.'

Practitioners believe that a Reiki treatment can be performed from a distance.

"A Reiki practitioner doesn't actually have any secret powers," said Reiki Master Erin Tschantret. "Anyone can practice Reiki. It's really, like, if a plumber were to open up a pipe and then suddenly water can flow through it, the practitioner is the pipe in the Reiki is the water. And it works on every level, so mental, emotional, physical, spiritual."

Tschantret's client, Rachel Garbow Monroe, said distance Reiki helped her fight COVID-19.

"The first time I talked to her when I was ill, I had had almost an entire week of a fever," Rachel Garbow Monroe said. "And the next day, my fever broke."

Tschantret's another client, writer and an author of a book "Zen Bender," in which she explored many alternative healing techniques of dealing with stress, Stephanie Krikorian, said distance Reiki has been helpful in the coronavirus era.

"People are afraid, we are at the end of our rope and feeling very stressed and anxious," Krikorian said. "You can do something without being near somebody, when we're all sort of separated and trying to hunker down and things are easing up a little, but everybody is still not comfortable."

Over the past 20 years, Reiki has become more and more popular in some of the most respected American hospitals, such as Yale Cancer Center.

Story continues

"I'm not going to be the first person to tell you that there's a ton of evidence behind it," said Dr. Gary Soffer, who runs the Integrative Medicine Program at the Cancer Center and Smilow Cancer Hospital in New Have, Connecticut. "But what I will tell you is that when we deal with patients one on one, it's really meaningful, and it's really helpful."

Several studies showed that Reiki helps diminish negative side effects of chemotherapy, recover from surgery, regulate nervous system, and deal with pain.

But there is no research paper that explains how Reiki works.

There is also no proof that healing energy can pass between people on command.

(Production: Aleksandra Michalska)

- They treating us like this.

- You are visualizing in your heart and minds the protesters, and the fear, and the anger, and all the things that are happening. And you are purposely giving them love and pure energy, health, stability, and positive strength.

- So what a Reiki practitioner does is they channel that energy to the person. So it's like you're getting flooded with this intense energy, knowledge, intelligence that knows how to get you to your best place. So it only ever works for your highest and greatest good. And it works on every level, so mental, emotional, physical, spiritual. And it helps get you back in alignment.

- I suffered both from COVID, and then a few weeks later, I had another acute illness. And she took care of being in touch with me and asking how I was doing. And you know, she believes very strongly in the power of Reiki, whether she's in the room or not.

And I leave it to you to determine the results. But I-- the first time I talked to her when I was ill, I had had almost an entire week of a fever. And she was incredibly sweet, and solicitous, and wanted to know how I was feeling and what specifically I was struggling with. And the next day, my fever broke.

- It's a great thing for the time. Distance Reiki, that you can do something without being near somebody when we're all sort of separated, and trying to hunker down. And things are easing up a little, but everybody's still not comfortable.

- The first question we ask ourselves in integrative medicine is, is this invasive? Is this going to be harmful to the patient? And then the next question is, is this helpful? Right? Is there evidence behind it?

So with Reiki, I'm not going to be the first person to tell you that there's a ton of evidence behind it. But what I will tell you is that when we deal with patients one on one, it's really meaningful, and it's really helpful. And because it's non-invasive, because it does no harm to our patients, it's a really meaningful and helpful intervention for them.

Original post:

Reiki that - how some Americans use alternative medicine to deal with stress - Yahoo News

Posted in Alternative Medicine | Comments Off on Reiki that – how some Americans use alternative medicine to deal with stress – Yahoo News

Impact of COVID-19 Outbreak on Complementary and Alternative Medicine Market to Witness Columbia Nutritional, Herb Pharm, Herbal Hills, Helio USA,…

Posted: at 3:11 pm

Complementary and Alternative Medicine Market 2020

This report studies the Complementary and Alternative Medicine Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Complementary and Alternative Medicine Market analysis segmented by companies, region, type and applications in the report.

The major players covered in Complementary and Alternative Medicine Market Columbia Nutritional, Herb Pharm, Herbal Hills, Helio USA, Deepure Plus, Nordic Naturals, Pure encapsulations, Iyengar Yoga Institute, John Schumachers Unity Woods Yoga Center, Yoga Tree, The Healing Company, and Quantum Touch

The final report will add the analysis of the Impact of Covid-19 in this report Complementary and Alternative Medicine industry.

Get a Free Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-complementary-and-alternative-medicine-market-size-status-and-forecast-2019-2025-one?utm_source=3wnews&utm_medium=36

Complementary and Alternative Medicine Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. The report also covers the list of Product range and Applications with SWOT analysis, CAGR value, further adding the essential business analytics. Complementary and Alternative Medicine Market research analysis identifies the latest trends and primary factors responsible for market growth enabling the Organizations to flourish with much exposure to the markets.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Research objectives:

To study and analyze the global Complementary and Alternative Medicine market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2026.

To understand the structure of Complementary and Alternative Medicine market by identifying its various sub segments.

Focuses on the key global Complementary and Alternative Medicine players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Complementary and Alternative Medicine with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of Complementary and Alternative Medicine submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The Complementary and Alternative Medicine Market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Table of Contents: Complementary and Alternative Medicine Market

Chapter 1: Overview of Complementary and Alternative Medicine Market

Chapter 2: Global Market Status and Forecast by Regions

Chapter 3: Global Market Status and Forecast by Types

Chapter 4: Global Market Status and Forecast by Downstream Industry

Chapter 5: Market Driving Factor Analysis

Chapter 6: Market Competition Status by Major Manufacturers

Chapter 7: Major Manufacturers Introduction and Market Data

Chapter 8: Upstream and Downstream Market Analysis

Chapter 9: Cost and Gross Margin Analysis

Chapter 10: Marketing Status Analysis

Chapter 11: Market Report Conclusion

Chapter 12: Research Methodology and Reference

Key questions answered in this report

What will the market size be in 2026 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Inquire More about This https://www.reportsandmarkets.com/enquiry/global-complementary-and-alternative-medicine-market-size-status-and-forecast-2019-2025-one?utm_source=3wnews&utm_medium=36

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

View post:

Impact of COVID-19 Outbreak on Complementary and Alternative Medicine Market to Witness Columbia Nutritional, Herb Pharm, Herbal Hills, Helio USA,...

Posted in Alternative Medicine | Comments Off on Impact of COVID-19 Outbreak on Complementary and Alternative Medicine Market to Witness Columbia Nutritional, Herb Pharm, Herbal Hills, Helio USA,…

Alternative APOE Gene Variants Associated with Different Diseases of Aging – JD Supra

Posted: at 3:11 pm

The inherent, ineluctable unpredictability of biology can be the basis for biological patent claims being non-obvious (lacking the requisite "reasonable expectation of success"; see, e.g., OSI Pharmaceuticals v. Apotex) and for the greater quantum of disclosure necessary to satisfy the written description and enablement requirements of 112 (see, e.g., Amgen v. Sanofi), despite complaints from the life sciences patent bar that these increased requirements are improper doctrinally and unfair. These two different characteristics can be frequently in tension for patenting in the life sciences, it being difficult to maintain on the one hand that there is insufficient expectation of success for a claim to be obvious and on the other hand that deficiencies in disclosure can be appropriately supplemented by the knowledge of one of ordinary skill.

This unpredictability was illustrated in a paper recently published in Nature Medicine, entitled "Common germline variants of the humanAPOE gene modulate melanoma progression and survival." These authors* showed (somewhat paradoxically) that one variant of the human APOE gene (APOE2) was associated with a propensity for tumor cells to metastasize, while a different variant (APOE4), which has been known for several years to be associated with development of Alzheimer's disease (see Strittmatter et al., 1993, Proc. Natl. Acad. Sci. USA 90: 1977-81), exhibited a metastasis-inhibiting effect (and APOE2 itself can have a protective effect on development of late-onset Alzheimer's; see Corder et al., 1994, Nat. Genet. 7: 180-84).

The experiments were performed in mice expressing human APOE4 or APOE2 by genetic replacement of the mouse analogs. Differences in melanoma tumor growth in these two mouse strains carrying these different human APOE genes were shown by comparing mouse melanoma tumor growth as shown in this Figure:

(where YUMM3.3 and YUMMER1.7 are murine melanoma cell lines).

The protective effects against metastasis of APOE4 were compared with APOE2 in these mice was demonstrated by tail vein injection of B16F10 melanoma cells, an established metastasis animal model. The human APOE4-bearing mice had a phenotype of enhanced anti-tumor immune response and improved outcomes under PD1 immune checkpoint blockade.

Because APOE was known to have modulatory effects on immune response, flow cytometric analysis of APOE gene variants in mice was performed and showed "enhanced recruitment of CD45+ leukocytes in animals bearing various melanoma tumors in APOE4 mice compared with APOE2 mice." Proportions of immune suppressor cells (Ly6G+ granulocytic myeloid-derived suppressor cells) were found to be diminished in APOE4-bearing mice, while these mice showed increased proportions of antitumor effector cells such as natural killer (NK) cells and CD8+ T cells. These results were confirmed by single-cell RNA sequencing for detecting lineage-specific gene expression. Further experiments showed that T cell depletion "completely abrogated" differences in melanoma tumor growth between human APOE4- and human APOE2-bearing mice. The authors concluded that "[t]hese data suggest that APOEgenotype modulated both the abundance and the functional state of the tumor immune microenvironment, with theAPOE4variant eliciting an enhanced anti-tumor immune profile relative to theAPOE2 variant." These authors also showed that APOE4 suppressed melanoma cell invasion and endothelial recruitment (involved in angiogenesis), which was consistent with lower blood vessel density in APOE4 mice.

In addition to these mouse studies, the authors assessed APOE genotype association in melanoma human patients from The Cancer Genome Atlas (TCGA). Neither of these APOE variants was enriched in the database, which the authors said indicated neither gene was involved in increased melanoma incidence. However, APEO4 carriers had improved survival, with 10.1 years for these patients versus 2.1 years for APEO2 carriers. This outcome was surprising due to the reduced longevity associated with APOE4 carriers, which the authors attributed to the high rates of melanoma-associated death. These results demonstrated that "germline genetic variants of APOEdifferentially associated with survival in patients with advanced melanoma who were at increased risk for melanoma-associated death and metastasis."

PD-1 immunotherapy is a commonly used treatment for melanoma, and "APOE4mice survived significantly longer thanAPOE2mice upon anti-PD1 treatment, suggesting thatAPOE genotype modulates melanoma outcome also in the context of immunotherapy," according to the results shown in the paper. In humans, "APOE4andAPOE2carriers exhibited the longest and shortest survival outcomes, respectively, upon anti-PD1 therapy," consistent with the results in mice.

The final set of experimental results reported in this paper involved pharmacologic activation of APOE through liver X receptors, which are "nuclear hormone receptors that transcriptionally activate several genes implicated in cholesterol and lipid metabolism, includingAPOE." In mice, this effect was completely abrogated in APOE2 mice but showed "robust anti-tumor effects" upon treatment in APOE4 mice. The authors concluded from these results that "distinct APOEgenotypes elicited differential responsiveness to LXR agonistic therapy and might serve as potential genetic biomarkers for current clinical efforts investigating the use of LXR agonism in cancer therapy."

The authors provide the following context for the results set forth in their paper:

Our findings have several potential clinical implications. Most importantly, they suggest that common germline variants might serve as biomarkers to identify patients with melanoma who are at high risk for metastatic relapse and melanoma-associated death for treatment with adjuvant systemic therapy. Notably, these clinical association findings will need to be assessed in prospective studies. It will be important to also assess the effect of APOE genotype on the outcome of additional cancer types. More generally, our findings support the notion that hereditary germline variants in the same gene can positively or negatively affect future progression and survival outcomes and responsiveness to therapy in a common human malignancy.

Authors: Benjamin N. Ostendorfa,Jana Bilanovica, Nneoma Adakua,Kimia N. Tafreshiana,Bernardo Tavoraa,Roger D. Vaughanb & Sohail F. Tavazoiea

a Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY, USAb Department of Biostatistics, The Rockefeller University, New York, NY, USA

Read the original:

Alternative APOE Gene Variants Associated with Different Diseases of Aging - JD Supra

Posted in Alternative Medicine | Comments Off on Alternative APOE Gene Variants Associated with Different Diseases of Aging – JD Supra

Is it Time to Introduce Homeopathy and Alternative Medicines to Fight against Covid-19? – thepolicytimes.com

Posted: at 3:11 pm

695 Views

Homeopathy is a pseudoscientific system of alternative medicine. It was created in 1796. In this pandemic, where many doctors and scientists are failed to find the Corona Virus Pandemic, there are some doctors are experts who believe homeopathy is the panacea of this fatal virus. Homeopathy has proved itself in several epidemics. It boosts immunity and increases the growth of the good bacteria in our body, which helps us to fight against any virus.

Father of Homeopathy, Dr. Samuel Hahnemann coined the phrase genus epidemics, which indicated the remedy which can cure any epidemic. Homeopathy has also helped cure the Spanish flu epidemic which happened after the First World War, plus, it has also proved its significance in curbing dengue and Swine flu.

It is published by the Ministry of AYUSH that homeopathic and Unani medicines could be effective in the prevention of novel coronavirus pandemic. It is recommended that homeopathic medicine Arsenical album 30 could be taken empty stomach daily for three days as a prophylactic medicine against the infection.

As we all know that, it has been more than three months for us fighting with this contagious Coronavirus disease. With the zeal to find the drug for this virus, one of the practioner of Homeopathy said that they should also be given the chance of testing the drug of this virus and they should also be considered on the same page as of other doctors. IANS, Dr. Kushal Banerjee, one of the largest and oldest practitioners of India and abroad, while speaking to News 18, has said that Homeopathy has a good track record with epidemics and infectious disease, therefore people should people should keep their biases aside and should try all treatments possible to save lives amid this pandemic.

But in the meantime, the major concern is, whether homeopathy is medicine for novel coronavirus disease or not? To answer this question, Dr. Banerjee said that There is not much data available about COVID-19. Homeopathic medicines are also given even in ICU and in case of multiple organ failure, patients start recovering quickly. There are very effective medicines in homeopathy for respiratory disease. Right now it is important to provide benefits to as many patients as possible. He further added that he and his team are in the process of analyzing data.

We are also running an online survey to estimate the result of that prescription. The database of 15000 people is ready. It will be the second-largest study on COVID-19 anywhere in the world; the largest is of 20000 patients. We have got responses from patients from 12 countries including the US, Italy, Norway, and Sweden. These data are looking very promising.

There are many myths about Homeopathy, and one of the greatest myths is that it a very long procedure and it will take a long time to cure. This myth has been neglected by Homeopathy doctors. According to them, the time depends on the disease. Homeopathy can cure some diseases in 2-3 hours and whereas some diseases can be cured within 15 minutes. They are also given to the patients on a ventilator. Homeopathic medicines are very effective, especially for respiratory disease.

Allopathic medicines may work a little bit faster as compared to Homeopathy, but it comes with some side-effects. Whereas, Homeopathic medicines are effective as well as there is no side-effect of them. Moreover, they are very beneficial to respiration. Thus, it may be concluded that now it time to bring Homeopathy in the fight against the Coronavirus.

Summary

Article Name

Is it Time to Introduce Homeopathy and Alternative Medicines to Fight against Covid-19?

Description

It is published by the Ministry of AYUSH that homeopathic and Unani medicines could be effective in the prevention of novel coronavirus pandemic. It is recommended that homeopathic medicine Arsenical album 30 could be taken empty stomach daily for three days as a prophylactic medicine against the infection.

Author

Kanupriya

Publisher Name

THE POLICY TIMES

Publisher Logo

See the original post here:

Is it Time to Introduce Homeopathy and Alternative Medicines to Fight against Covid-19? - thepolicytimes.com

Posted in Alternative Medicine | Comments Off on Is it Time to Introduce Homeopathy and Alternative Medicines to Fight against Covid-19? – thepolicytimes.com

Easing of Covid-19 restrictions: More UAE residents explore alternative immunity boosters – Khaleej Times

Posted: at 3:11 pm

Alternative medical therapies are back in business and increasingly gaining traction from the public with the easing of Covid-19 restrictions. Stress management therapies and immune system boosters are seeing a rise in takers after Dubai resumed complementary medicine therapies.

Health care professionals have welcomed this move as it also brings the much needed economic relief to most clinics as well as reassuring patients with their continued treatment which was disrupted due to Covid-19 pandemic.

To put patients at ease and keep them safe, these clinics are implementing a slew of hygiene measures as per the guidelines laid down by the Dubai Health Authority (DHA).

"With all our walk-in patients we first check the temperature and in case, there is any doubt patients are sent for swab tests. Apart from that all other precautionary measures are in place. We have also noticed there are too many people who are in a panic mode now. So, special ayurvedic treatment or therapies focused on this aspect is clearly on the rise," said Shameema Abdul Nazar, ayurvedic practitioner at Metro Medical Centre.

"Health awareness for all age groups is becoming important which entails different herbal preparations, yoga therapy or breathing exercises pertaining to strengthening one's lungs, managing panic and improving sleep are seeing demand," she added.

Life coach and energy healer Girish Hemnani said: "It's encouraging to see more individuals seeking to learn and practice breath work and energy healing as it is instrumental in increasing the immune system. As an energy healer, for the first time I am witnessing that individuals are looking for protective measures and natural ways to increase and maintain their immune system. Prana (life force energy, also known as chi) is being well understood now and various techniques to increase the prana level are being practised."

Homeopathic doctors are also observing a sizeable increase in demand now. "The demand for general immunisation treatment or a need for immunity booster is witnessing a surge. People with active fever are asked a set of questions on the phone first and are routed differently depending on the nature of their replies," said Dr Rozina Baig Zaheer, homeopathic practitioner at Zia Medical Centre.

"However, I am noticing an increase in anxiety cases these days. My patients are relieved that they can finally continue with their preexisting treatment related to a host of other problems. We are back to offering customised treatment on a case-by-case basis," she added.

Using natural herbs to cure different types of diseases, a traditional Chinese medicinal facility located in Dubai Healthcare City, continues to offer certain in-house procedures on an urgent basis. "We provide a complete array of services, from consultation, herbalism, acupuncture, acupressure, cupping and Tui-Na (remedial massage). But right now, patients are prioritised. For example, recently we've been treating a patient with facial paralysis. For all non-urgent cases, we use teleconsultation and delivering medicines at the patients' doorstep," said Deyuan Wei, director of Beijing Tong Ren Tang.

nandini@khaleejtimes.com

Continued here:

Easing of Covid-19 restrictions: More UAE residents explore alternative immunity boosters - Khaleej Times

Posted in Alternative Medicine | Comments Off on Easing of Covid-19 restrictions: More UAE residents explore alternative immunity boosters – Khaleej Times